Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: The risk of recurrence after radical surgery performed for pancreatic neuroendocrine tumors (PanNET) is reported between 10 and 30%. Nowadays, no adjuvant therapy is recommended for these patients and specific treatments are offered only when recurrence occurs. Nevertheless, among the available systemic and locoregional treatments, there are no specific recommendations on which the best option could be for treating recurrent disease.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Andreasi V
Authors: Andreasi V, Partelli S, Landoni L, Nessi C, Muffatti F,
Keywords: pancreatic neuroendocrine tumors, recurrence, surgery, locoregional treatment, systemic treatment,
Introduction: New systemic treatments have improved the therapeutic landscape for patients with progressive, metastatic GEP-NETs. While drugs such as everolimus are appropriate for patients with widespread disease progression, local treatment approaches may be more appropriate for patients with unifocal progression.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Strosberg J
Authors: Al-Toubah T, Cives M, Anaya D, Soares H, Strosberg J,
Keywords: GEP-NET, locoregional treatment, ablation, embolization, surgical resection, neuroendocrine tumor, systemic therapy, external beam radiation,
Introduction: Trans-arterial embolization (TAE) and chemoembolization (TACE) have been shown to be effective in patients (pts) with liver metastases (LM) from gastroenteropancreatic neuroendocrine tumor (GEP NET). TAE and TACE goal is to reduce blood flow to the tumor resulting in ischemia and necrosi.
Conference: 9th Annual ENETSConcerence (2012)
Presenting Author:
Authors: Del Prete M, Faggiano A, Marotta V, Ramundo V, Marciello F,